Cotylenin A|CAS 12708-37-1|DC Chemicals

Cas No.:	12708-37-1
Chemical Name:	Cotylenin A
SMILES:	COC[C@@H](O[C@@H]1O[C@@H]([C@@H]([C@@H]2C)O)C([C@@](/C=C3[C@@]2([H])CC[C@@](O)\3COC)(CC4)C)=C4C(C)C)[C@@]5(O[C@]6([C@]7([H])CO7)C)[C@]([C@H]1O)([H])O[C@@]6([H])O5
Formula:	C₃₃H₅₀O₁₁
M.Wt:	622.74
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC71559	IZTZ-1	IZTZ-1, an imidazole-benzothiazole conjugate, is a c-MYC G4 ligand. IZTZ-1 is able to downregulate the c-MYC expression by stabilizing c-MYC G4. IZTZ-1 induces cell cycle arrest, apoptosis, thereby inhibiting cell proliferation in B16 cells. IZTZ-1 shows antitumor activity, and can be used for melanoma research.
DC70631	MYCMI-7	MYCMI-7 is a small molecule MYC-binding compound (Kd=4 uM) that inhibits MYC-MAX interaction.MYCMI-7 efficiently and selectively inhibits MYC:MAX and MYCN:MAX interactions in cells, binds directly to recombinant MYC, and reduces MYC-driven transcription.MYCMI-7 induces degradation of MYC and MYCN proteins.MYCMI-7 potently induces growth arrest/apoptosis in tumor cells in a MYC/MYCN-dependent manner and downregulates the MYC pathway on a global level.MYCMI-7 downregulates MYC/MYCN, inhibits tumor growth, and prolongs survival through apoptosis in mouse tumor models of MYC-driven AML, breast cancer, and MYCN-amplified neuroblastoma.
DC44757	EN4	EN4, a covalent ligand that targets cysteine 171 (C171) of MYC, is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.
DC10952	MYCMI-6(NSC 354961)	MYCMI-6 (NSC354961) is a selective, high affinity inhibitor of MYC-MAX interaction, blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with Kd of 1.6 uM in SPR assay.
DC76995	NSC308848	NSC308848 is a potent apoptosis inducer in a Myc-dependent manner. NSC308848 inhibits Myc transactivation and interferes with the DNA-binding activity of Myc family proteins.
DC76994	KL4-219A	KL4-219A is a selective covalent oncogenic transcription factor MYC degrader. KL4-219A potently and durably degrades MYC in cancer cells. KL4-219A binds covalently to MYC at C203, leading to the destabilization of MYC and subsequent proteasome-dependent degradation. KL4-219A is promising for research of cancers driven by MYC overexpression.
DC76993	Cotylenin A	Cotylenin A is a type of phenanthraquinone compound that works alongside vitamin K2 to induce the differentiation of monocytes and halt their growth, while also inhibiting the expression of c-Myc and inducing the expression of cyclin G2 in human leukemia HL-60 cells. Cotylenin A can be used in studies on acute myeloid leukemia.
DC76992	(-)-CMLD010509	(-)-CMLD010509 ((-)-SDS-1-021) is an isomer of CMLD010509 (SDS-1-021). DOTAGA-FAP-2286-ALB is a selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 67.5 nM. DOTAGA-FAP-2286-ALB enhances tumor retention via albumin interaction, prolonging blood circulation and improving radiometal complex stability (e.g., with 111In and 225Ac). DOTAGA-FAP-2286-ALB is promising for research of radionuclide therapy (TRT) of FAP-positive solid tumors.
DC73816	VPC-70619	VPC-70619 (VPC70619) is a selective small-molecule inhibitor of N-Myc transcription in NMYC transcription inhibition assays.
DC73815	NSC13728 hydrochloride	NSC13728 hydrochloride is a specific small molecule stabilizer of the Max homodimer inhibiting Myc function, also inhibits Myc-Max heterodimerization.